Vitamin D and multiple sclerosis

Journal of Cellular Biochemistry

Volumn 105, Issue 2, 2008, Pages 338-343

  Raghuwanshi, Anita ^a   Joshi, Sneha S ^a   Christakos, Sylvia ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

1,25 Dihdyroxyvitamin D3; Immune function; Multiple sclerosis; Review; Sunlight; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; VITAMIN D DERIVATIVE;

HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SOLAR RADIATION; SUN EXPOSURE; SUNLIGHT; ULTRAVIOLET IRRADIATION; VITAMIN METABOLISM;

HUMANS; MULTIPLE SCLEROSIS; PROTECTIVE AGENTS; ULTRAVIOLET RAYS; VITAMIN D;

EID: 54849432596     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21858     Document Type: Review

References (66)

1. Abe J, Nakamura K, Takita Y, Nakano T, Irie H, Nishii Y. 1990. Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha,25-dihydroxyvitamin D3. J Nutr Sci Vitaminol (Tokyo) 36:21-31.
2. Alroy I, Towers TL, Freedman LP. 1995. Transcriptional repression of the interleukin-2 gene by vitamin D3: Direct inhibition of NFATp/AP-1 complex formationby a nuclear hormone receptor. Mol Cell Biol 15:5789-5799.
3. Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. 1983. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: Presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 57:1308-1310.
4. Bhalla AK, Amento EP, Krane SM. 1986. Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: Inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol 98:311-322.
5. Cantorna MT, Hayes CE, DeLuca HF. 1996. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci 93:7861-7864.
6. Cantorna MT, Hayes CE, DeLuca HF. 1998a. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 128:68-72.
7. Cantorna MT, Woodward WD, Hayes CE, DeLuca HF. 1998b. 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol 160:5314-5319.
8. Cantorna MT, Humpal-Winter J, DeLuca HF. 1999. Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. J Nutr 129:1966-1971.
9. Cantorna MT, Humpal-Winter J, DeLuca HF. 2000. In vivo upregulation of interleukin-4 is one mechanism underlying the immunoregulatory effects of 1,25-dihydroxyvitamin D(3). Arch Biochem Biophys 377:135-138.
10. Christakos S, Dhawan P, Liu Y, Peng X, Porta A. 2003. New insights into the mechanisms of vitamin D action. J Cell Biochem 88:695-705.
11. Christakos S, Dhawan P, Benn B, Porta A, Hediger M, Oh GT, Jeung EB, Zhong Y, Ajibade D, Dhawan K, Joshi S. 2007. Vitamin D: Molecular mechanism of action. Ann NY Acad Sci 1116:340-348.
12. Cippitelli M, Santoni A. 1998. Vitamin D3: A transcriptional modulator of the interferon-gamma gene. Eur J Immunol 28:3017-3030.
13. D'Ambrosio D, Cippitelli M, Cocciolo MG, Mazzeo D, Di Lucia P, Lang R, Sinigaglia F, Panina-Bordignon P. 1998. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 101:252-262.
14. DeLuca HF. 2004. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80:1689S-1696S.
15. DeLuca HF, Cantorna MT. 2001. Vitamin D: Its role and uses in immunology. FASEB J 15:2579-2585.
16. Fontoura P, Steinman L, Miller A. 2006. Emerging therapeutic targets in multiple sclerosis. Curr Opin Neurol 19:260-266.
17. Fournier C, Gepner P, Sadouk M, Charreire J. 1990. In vivo beneficial effects of cyclosporin A and 1,25-dihydroxyvitamin D3 on the induction of experimental autoimmune thyroiditis. Clin Immunol Immunopathol 54:53-63.
18. Freedman DM, Dosemeci M, Alavanja MC. 2000. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: A case-control study based on death certificates. Occup Environ Med 57:418-421.
19. Gascon-Barre M, Huet PM. 1983. Apparent [3H]1,25-dihydroxyvitamin D3 uptake by canine and rodent brain. Am J Physiol 244:E266-E271.
20. Goldberg P. 1974. Multiple sclerosis: Vitamin D and calcium as environmental determinants of prevalence; (A viewpoint) part 1: Sunlight, dietary factors and epidemiology. Int J Environ Stud 6:19-27.
21. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L. 2002. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 51:1367-1374.
22. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. 2001. Dendritic cell modulation by 1alpha, 25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci 98:6800-6805.
23. Hammond SR, English DR, McLeod JG. 2000. The age-range of risk of developing multiple sclerosis: Evidence from a migrant population in Australia. Brain 123:968-974.
24. Hathcock JN, Shao A, Vieth R, Heaney R. 2007. Risk assessment for vitamin D. Am J Clin Nutr 85:6-18.
25. Hauser SL, Oksenberg JR. 2006. The neurobiology of multiple sclerosis: Genes, inflammation, and neurodegeneration. Neuron 52:61-76.
26. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux. MJ. 2003. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 77:204-210.
27. Hine TJ, Roberts NB. 1994. Seasonal variation in serum 25-hydroxy vitamin D3 does not affect 1,25-dihydroxy vitamin D. Ann Clin Biochem 31:31-34.
28. Holick MF. 1995. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr 61:638S-645S.
29. Holick MF. 2002. Vitamin D: The underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin in Endocrinol Diab 9:87-98.
30. Holick MF. 2007. Vitamin D deficiency. N Engl J Med 357:266-281.
31. Kampman MT, Wilsgaard T, Mellgren SI. 2007. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 254:471-477.
32. Kurtzke JF. 1967. On the fine structure of the distribution of multiple sclerosis. Acta Neurol Scand 43:257-282.
33. Kurtzke JF. 2000. Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio Doctoralis. Neurol Sci 21:383-403.
34. Lemire JM, Archer DC. 1991. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 87:1103-1107.
35. Liu PT, Stenger S, Tang DH, Modlin RL. 2007. Cutting edge: Vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 179:2060-2063.
36. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. 1994. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 37:552-558.
37. Matsuoka LY, Ide L, Wortsman J, MacLaughlin JA, Holick MF. 1987. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab 64:1165-1168.
38. Matsuoka LY, Wortsman J, Dannenberg MJ, Hollis BW, Lu Z, Holick MF. 1992. Clothing prevents ultraviolet-B radiation-dependent photosynthesis of vitamin D3. J Clin Endocrinol Metab 75:1099-1103.
39. Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, Poliani PL, Martino G, Panina-Bordignon P, Adorini L. 2000. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur J Immunol 30:498-508.
40. Meehan TF, DeLuca HF. 2002. CD8(R) T cells are not necessary for 1 alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Proc Natl Acad Sci 99:5557-5560.
41. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. 2006. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832-2838.
42. Muthian G, Raikwar HP, Rajasingh J, Bright JJ. 2006. 1,25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J Neurosci Res 83: 1299-1309.
43. Nashold FE, Hoag KA, Goverman J, Hayes CE. 2001. Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J Neuroimmunol 119:16-29.
44. Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN, Goltzman D. 2001. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: Evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci 98:7498-7503.
45. Pedersen LB, Nashold FE, Spach KM, Hayes CE. 2007. 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res 85:2480-2490.
46. Penna G, Adorini L. 2000. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164:2405-2411.
47. Prufer K, Veenstra TD, Jirikowski GF, Kumar R. 1999. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord. J Chem Neuroanat 16:135-145.
48. Pugliatti M, Sotgiu S, Rosati G. 2002. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104:182-191.
49. Rachez C, Freedman LP. 2000. Mechanisms of gene regulation by vitamin D(3) receptor: A network of coactivator interactions. Gene 246:9-21.
50. Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M, Naar AM, Erdjument-Bromage H, Tempst P, Freedman LP. 1999. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 398:824-828.
51. Reichel H, Koeffler HP, Tobler A, Norman AW. 1987. 1 alpha,25- Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci 84:3385-3389.
52. Rigby WF. 1988. The immunobiology of vitamin D. Immunol Today 9:54-58.
53. Shultz TD, Fox J, Heath H, III, Kumar R. 1983. Do tissues other than the kidney produce 1,25-dihydroxyvitamin D3 in vivo? A reexamination. Proc Natl Acad Sci 80:1746-1750.
54. Spach KM, Hayes CE. 2005. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 175:4119-4126.
55. Spach KM, Nashold FE, Dittel BN, Hayes CE. 2006. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 177:6030-6037.
56. Stumpf WE, O'Brien LP. 1987. 1,25 (OH)2 vitamin D3 sites of action in the brain. An autoradiographic study. Histochemistry 87:393-406.
57. Stumpf WE, Sar M, Clark SA, DeLuca HF. 1982. Brain target sites for 1,25-dihydroxyvitamin D3. Science 215:1403-1405.
58. Stumpf WE, Clark SA, O'Brien LP, Reid FA. 1988. 1,25(OH)2 vitamin D3 sites of action in spinal cord and sensory ganglion. Anat Embryol (Berl) 177:307-310.
59. Sutton AL, MacDonald PN. 2003. Vitamin D: More than a "bone-a-fide" hormone. Mol Endocrinol 17:777-791.
60. Tobler A, Gasson J, Reichel H, Norman AW, Koeffler HP. 1987. Granulocyte-macrophage colony-stimulating factor. Sensitive and receptor-mediated regulation by 1,25-dihydroxyvitamin D3 in normal human peripheral blood lymphocytes. J Clin Invest 79:1700-1705.
61. Towers TL, Freedman LP. 1998. Granulocyte-macrophage colony-stimulating factor gene transcription is directly repressed by the vitamin D3 receptor. Implications for allosteric influences on nuclear receptor structure and function by a DNA element. J Biol Chem 273:10338-10348.
62. van der Mei IA, Ponsonby AL, Blizzard L, Dwyer T. 2001. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 20:168-174.
63. van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, Butzkueven H, Kilpatrick T. 2003. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. Br Med J 327:316.
64. van Etten E, Gysemans C, Branisteanu DD, Verstuyf A, Bouillon R, Overbergh L, Mathieu C. 2007. Novel insights in the immune function of the vitamin D system: Synergism with interferon-beta. J Steroid Biochem Mol Biol 103:546-551.
65. Vieth R. 1999. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 69:842-856.
66. Webb AR, Kline L, Holick MF. 1988. Influence of season and latitude on the cutaneous synthesis of vitamin D3: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 67:373-378.